Compare Nutrien Ltd (NTR) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutrien Ltd vs GeneDx Holdings Corp — how do they compare? Nutrien Ltd trades at $67.48 (market cap $33.31B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Nutrien Ltd is far larger — about 16.5× GeneDx Holdings Corp's market cap, and Nutrien Ltd pays a 3.15% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nutrien Ltd for 59 Days and GeneDx Holdings Corp for 19 Days on average.
| NTR | WGS | |
|---|---|---|
Market Cap | $33.31B | $2.02B |
Volume | 1,330,729 | 734,640 |
Sector | Basic Materials | Health |
52-Week High | $83.94 | $167.51 |
52-Week Low | $53.64 | $34.51 |
Typical Hold Time | 59 Days | 19 Days |
Enterprise Value | $45.11B | $2.05B |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTR trades at $67.48, down 3.56% over 24 hours, with technical indicators showing a bearish trend. The company reported mixed quarterly earnings, missing Q4 2025 and Q2 2026 EPS estimates but beating in Q1 2026. Financials show a net income margin of 8.44% for 2025, with revenue of $26.89B, while recent news highlights industry headwinds from potential U.S. potash deals with Belarus.
The outlook is cautious; analyst consensus is a Moderate Buy with a $76.14 price target, but near-term risks include volatile fertilizer prices and competitive pressures. Long-term demand for agricultural inputs supports fundamentals, yet investors face cyclical earnings and margin compression risks amid macroeconomic uncertainty.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
